Nuzhat Ahmed
Overview
Explore the profile of Nuzhat Ahmed including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
80
Citations
2817
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wesley T, Escalona R, Kannourakis G, Ahmed N
Cancers (Basel)
. 2024 Dec;
16(23).
PMID: 39682273
Epithelial ovarian cancer is aggressive and causes high mortality among women worldwide. Members of the plakin family are essential to maintain cytoskeletal integrity and key cellular processes. In this study...
2.
Sharma R, Balta S, Raza A, Escalona R, Kannourakis G, Prithviraj P, et al.
Cancers (Basel)
. 2023 May;
15(9).
PMID: 37174052
The process of epithelial-mesenchymal transition (EMT) involves the phenotypic transformation of cells from epithelial to mesenchymal status. The cells exhibiting EMT contain features of cancer stem cells (CSC), and the...
3.
Escalona R, Chu S, Kadife E, Kelly J, Kannourakis G, Findlay J, et al.
Cancer Cell Int
. 2022 Dec;
22(1):422.
PMID: 36585738
Background: The endogenous tissue inhibitor of metalloproteinase-2 (TIMP-2), through its homeostatic action on certain metalloproteinases, plays a vital role in remodelling extracellular matrix (ECM) to facilitate cancer progression. This study...
4.
Leung D, Price Z, Lokman N, Wang W, Goonetilleke L, Kadife E, et al.
J Transl Med
. 2022 Dec;
20(1):556.
PMID: 36463238
Background: Epithelial ovarian cancer is the most lethal gynaecological cancer worldwide. Chemotherapy resistance represents a significant clinical challenge and is the main reason for poor ovarian cancer prognosis. We identified...
5.
Sharma R, Kannourakis G, Prithviraj P, Ahmed N
Front Med (Lausanne)
. 2022 Jul;
9:766869.
PMID: 35775004
Renal cell cancer (RCC) is a heterogeneous tumor that shows both intra- and inter-heterogeneity. Heterogeneity is displayed not only in different patients but also among RCC cells in the same...
6.
Escalona R, Kannourakis G, Findlay J, Ahmed N
Front Oncol
. 2022 Jan;
11:796588.
PMID: 35047406
Background: The tissue inhibitors of metalloproteinase (TIMPs) and their associated metalloproteinase (MMPs) are essential regulators of tissue homeostasis and are essential for cancer progression. This study analyzed the expression of...
7.
Zhai J, Tan F, Luwor R, Reddy T, Ahmed N, Drummond C, et al.
ACS Appl Bio Mater
. 2022 Jan;
3(7):4198-4207.
PMID: 35025421
Cubosomes with an internal three-dimensional (3D) periodic and porous particulate nanostructure have emerged as a promising drug delivery system for hydrophobic small molecules as well as large biomolecules over the...
8.
Sharma R, Kadife E, Myers M, Kannourakis G, Prithviraj P, Ahmed N
J Exp Clin Cancer Res
. 2021 Jun;
40(1):186.
PMID: 34099013
Vascular endothelial growth factor tyrosine kinase inhibitors (VEGF-TKIs) have been the mainstay of treatment for patients with advanced renal cell carcinoma (RCC). Despite its early promising results in decreasing or...
9.
Wesley T, Berzins S, Kannourakis G, Ahmed N
Cell Commun Signal
. 2021 May;
19(1):55.
PMID: 34001250
The plakin family of cytoskeletal proteins play an important role in cancer progression yet are under-studied in cancer, especially ovarian cancer. These large cytoskeletal proteins have primary roles in the...
10.
Escalona R, Bilandzic M, Western P, Kadife E, Kannourakis G, Findlay J, et al.
BMC Cancer
. 2020 Oct;
20(1):960.
PMID: 33023532
Background: The metzincin family of metalloproteinases and the tissue inhibitors of metalloproteinases (TIMPs) are essential proteins required for biological processes during cancer progression. This study aimed to determine the role...